Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial
Hematological Oncology · 2023
DOI: 10.1002/hon.3117 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Hematological Oncology, 2023. Verfasst von Alberto Biggi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Division, Santa Croce e Carle Hospital, Cuneo, Italy. Hauptthemen laut MEDLINE: Hodgkin Disease. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Associazione Italiana Contro le Leucemie-Linfomi e Mieloma, Fondazione Cassa di Risparmio di Cuneo, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
The Lugano classification for response assessment in lymphoma recommends the use of the 5‐point‐scale Deauville Score (DS) to assess response evaluation of end‐of‐treatment FDG‐PET/CT (eotPET) in Hodgkin Lymphoma (HL); nevertheless, there is a paucity of data on its accuracy and reproducibility. We focus here on the cohort of advanced stage IIb‐IV HL patients enrolled in the HD0607 clinical trial (NCT identifier 00795613) that having had a negative interim PET performed 6 cycles of ABVD (Doxorubicin, Vinblastine, Vincristine and Dacarbazine) and then performed an eotPET. Negative patients were randomized to radiotherapy and no further treatment while positive patients were treated based on local policies. eotPET was re‐evaluated independently by two readers evaluated and progression free survival was analysed (PFS). eotPET of 254 patients were analysed. The median follow‐up was 43 months. The best receiver operator characteristics cut‐off values to distinguish positive and negative patients was 4. The area‐under‐the‐curve was 0.81 (95%CI, 0.70–0.91). Three‐years PFS was 0.95 (95% CI 0.90–0.97) in eotPET negative and 0.22 (95% CI 0.11–0.43) in eotPET positive. DS demonstrated a good reproducibility of positivity/negativity between the readers consensus and local site evaluation where the agreement occurred on 95.0% of patients. The present study demonstrates that eotPET is an accurate tool to predict treatment outcome in HL and confirms the appropriateness of the Lugano classification for eotPET evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Division, Santa Croce e Carle Hospital, Cuneo, Italy.
- Medical Physics Division, Santa Croce e Carle Hospital, Cuneo, Italy.
- Nuclear Medicine Division, IRCSS Ospedale San Raffaele, Milano, Italy.
- Nuclear Medicine Division, Ospedale San Gerardo, Monza, Italy.
- Nuclear Medicine Division, Ospedale Trieste, Trieste, Italy.
- Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
ORCID-Profile: Stephane Chauvie, Livio Trentin
Förderung
- Associazione Italiana Contro le Leucemie-Linfomi e Mieloma
- Fondazione Cassa di Risparmio di Cuneo
- Associazione Italiana per la Ricerca sul Cancro
Zitieren
APA
Biggi, A., Chauvie, S., Fallanca, F., Guerra, L., Bergesio, F., Menga, M., Bianchi, A., Gregianin, M., Chiaravalloti, A., Schillaci, O., Pavoni, C., Patti, C., Picardi, M., Romano, A., Schiavotto, C., Sorasio, R., Viviani, S., La Nasa, G., Trentin, L., …, & Gallamini, A. (2023). Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial. Hematological Oncology. https://doi.org/10.1002/hon.3117
Vancouver
Biggi A, Chauvie S, Fallanca F, Guerra L, Bergesio F, Menga M, et al. Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial. Hematological Oncology. 2023. doi:10.1002/hon.3117
BibTeX
@article{Biggi2023,
author = {Biggi, Alberto and Chauvie, Stephane and Fallanca, Federico and Guerra, Luca and Bergesio, Fabrizio and Menga, Massimo and Bianchi, Andrea and Gregianin, Michele and Chiaravalloti, Agostino and Schillaci, Orazio and Pavoni, Chiara and Patti, Caterina and Picardi, Marco and Romano, Alessandra and Schiavotto, Corrado and Sorasio, Roberto and Viviani, Simonetta and La Nasa, Giorgio and Trentin, Livio and Rambaldi, Alessandro and Gallamini, Andrea},
title = {Predictive value on advance hodgkin lymphoma treatment outcome of end‐of treatment FDG PET/CT in the HD0607 clinical trial},
journal = {Hematological Oncology},
year = {2023},
doi = {10.1002/hon.3117}
}
EUVIMED